CytomX Therapeutics Financials - Benzinga

CytomX Therapeutics Inc

CTMXNASDAQ

Trade with Public

Trade with Public

$3.35

-0.025-0.74%

Last update: Aug 26, 2:14 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

CytomX Therapeutics Financials

CytomX Therapeutics (CTMX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which

Benzinga Newsdesk

PRO
CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.20) by 50 percent. This is a 137.04 percent decrease over earnings of $0.27 per share from

Benzinga Newsdesk

Earnings Scheduled For March 16, 2026

Benzinga Insights

PRO
CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.09) by 136.56 percent. This is a 195.65 percent decrease over earnings of $0.23 per

Benzinga Newsdesk

PRO
CytomX Therapeutics Q3 EPS $(0.09) Misses $(0.05) Estimate, Sales $5.963M Miss $11.625M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 95.65 percent. This is a 228.57 percent decrease over earnings of $0.07 per share

Benzinga Newsdesk

Earnings Scheduled For November 6, 2025

Benzinga Insights